JECTABUTAZONE 20%
JECTABUTAZONE 20%
JECTABUTAZONE 20%
Solution for injection
(For vet. use only)
JECTABUTAZONE 20%
Each 1 ml contains:
Active ingredient: Phenylbutazone 200 mg/ml
Active ingredient: Phenylbutazone 200 mg/ml
– Phenylbutazone is a pyrazolone derivative belonging to the group of the non – steroidal anti – inflammatory drugs.
– Phenylbutazone inhibits the cyclooxygenase enzyme and interferes thus with the formation of cyclic endoperoxides, prostacyclin, and prostaglandins thromboxanes.
– The anti- inflammatory effect appears only in the inflammatory tissue if there is an accumulation Sufficient of phenylbutazone and the amount of prostaglandin has processed.
– Phenylbutazone also exerts a stabilizing action on the capillary wall and the lysosomal membranes, which inhibits inflammatory responses in the same time.
– The anti – inflammatory activity of phenylbutazone (inhibition of peripheral prostaglandin), is considerably (inhibition of central prostaglandin).
– Phenylbutazone inhibits the cyclooxygenase enzyme and interferes thus with the formation of cyclic endoperoxides, prostacyclin, and prostaglandins thromboxanes.
– The anti- inflammatory effect appears only in the inflammatory tissue if there is an accumulation Sufficient of phenylbutazone and the amount of prostaglandin has processed.
– Phenylbutazone also exerts a stabilizing action on the capillary wall and the lysosomal membranes, which inhibits inflammatory responses in the same time.
– The anti – inflammatory activity of phenylbutazone (inhibition of peripheral prostaglandin), is considerably (inhibition of central prostaglandin).
Reatment of musculoskeletal disorders in horses and dogs where the anti-inflammatory and analgesic properties of phenylbutazone can offer relief against inflammation, pain and lameness (for example, osteoarthritis, acute and chronic laminitis, bursitis and carpitis).
horses and dogs.
Horses: (2.2 ml / 100 kg of body weight / injection) once daily for up to 5 days.
Dogs: 0.75 ml / 10 kg weight bow / injection) in a single dose.
Dogs: 0.75 ml / 10 kg weight bow / injection) in a single dose.
– In case of decreased hepatic or renal function of animals (mainly in animals older ), it is recommended to reduce the dose.
– Inject slowly strictly intravenously. Rapid intravenous injection can be at the origin of a local phlebitis.
Perivascular injections can cause Severe inflammation and necrosis at the injection site.
– Do not use before surgery.
– Administer only to adult animals.
– The dogs are very sensitive to the ulcerogenic effects of this product on the gastrointestinal mucosa, even when take the therapeutic doses.
– The indicated dose or treatment duration cannot be exceeded.
– Using the product is not recommended during pregnancy and lactation.
– Phenylbutazone affect the action of many pharmaceuticals, firstly by protein binding and displacement of the other by an interference at the renal excretion (tubular secretion).
– Phenylbutazone increases the plasma levels of these:
Sulfonamides, corticosteroids, anticoagulants.
products. – phenylbutazone decreases the uricosuric action for salicylics derivatives.
– phenylbutazone prolongs plasma half.
– life for Penicillin and its derivatives.
– Phenylbutazone should not be used when processing with podotrochlear warfarin.
– It is not recommended to treat dogs intravenously over two consecutive days.
– Do not use in animals intended for human consumption.
– Do not use in new –born domestic animals. This product contains benzyl alcohol which has been documented to cause adverse reactions in neonates.
– Inject slowly strictly intravenously. Rapid intravenous injection can be at the origin of a local phlebitis.
Perivascular injections can cause Severe inflammation and necrosis at the injection site.
– Do not use before surgery.
– Administer only to adult animals.
– The dogs are very sensitive to the ulcerogenic effects of this product on the gastrointestinal mucosa, even when take the therapeutic doses.
– The indicated dose or treatment duration cannot be exceeded.
– Using the product is not recommended during pregnancy and lactation.
– Phenylbutazone affect the action of many pharmaceuticals, firstly by protein binding and displacement of the other by an interference at the renal excretion (tubular secretion).
– Phenylbutazone increases the plasma levels of these:
Sulfonamides, corticosteroids, anticoagulants.
products. – phenylbutazone decreases the uricosuric action for salicylics derivatives.
– phenylbutazone prolongs plasma half.
– life for Penicillin and its derivatives.
– Phenylbutazone should not be used when processing with podotrochlear warfarin.
– It is not recommended to treat dogs intravenously over two consecutive days.
– Do not use in animals intended for human consumption.
– Do not use in new –born domestic animals. This product contains benzyl alcohol which has been documented to cause adverse reactions in neonates.
– Risk of bleeding.
– Gastrointestinal irritation, gastrointestinal damage, stomach ulcers.
– Blood count abnormalities.
– Renal papillary necrosis of the kidney.
– Gastrointestinal irritation, gastrointestinal damage, stomach ulcers.
– Blood count abnormalities.
– Renal papillary necrosis of the kidney.
Dogs: Not applicable.
Horse: Do not use in animals intended for human consumption.
Horse: Do not use in animals intended for human consumption.
Store at temperature not exceeding 30o c and used immediately after opening.
Carton box containing amber glass vial (type I) containing 20, 50, 100, 250, 500 ml and 1 Liter injectable solution closed by chlorobutyl rubber stopper sealed with aluminum cap covered with central tear off plastic cover with outer label + inner leaflet.